An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer

被引：31

作者：

Hotta, K ^{[1
]}

Ueoka, H ^{[1
]}

Kiura, K ^{[1
]}

Tabata, M ^{[1
]}

Tanimoto, M ^{[1
]}

机构：

[1] Okayama Univ, Sch Med, Dept Med 2, Okayama 7008558, Japan

来源：

LUNG CANCER | 2004年 / 46卷 / 01期

关键词：

elderly patient; clinical trial; non-small cell lung cancer; calendar age; chemotherapy; vinorelbine;

D O I：

10.1016/j.lungcan.2004.02.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: The aim of the present study was to identify elderly-specific clinical trials for advanced non-small cell lung cancer (NSCLC) and to clarify the study design and patient characteristics entered of each of these trials. Methods: We used the MEDLINE database to select prospective clinical trials evaluating the efficacy of chemotherapy in elderly patients with advanced NSCLC. Results: Our literature search yielded 48 prospective clinical trials between 1990 and 2003, involving a total of 2648 elderly patients with advanced NSCLC. The median number of patients treated per trial was 36. In 23 (48%) of the 48 trials, only the abstract was available. In 44 trials (92%), elderly patients were defined using their calendar age, and the age of 70 years was the most frequently used lower limit for inclusion. Vinorelbine was the most widely studied chemotherapy agent in elderly patients. Conclusions: Our review revealed that (i) the definition of "elderly" varied from trial to trial, and elderly patients were simply defined using calender age in the clinical trials; (ii) the quality of elderly-specific trials were generally poor, mainly because of their small sample size. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

引用

页码：61 / 76

页数：16

共 94 条

[11] Estimates of cancer incidence and mortality in Europe in 1995 [J].

Bray, F ;

Sankila, R ;

Ferlay, J ;

Parkin, DM .

EUROPEAN JOURNAL OF CANCER, 2002, 38 (01) :99-166

[12]

Buccheri G, 2000, CANCER-AM CANCER SOC, V88, P2677, DOI 10.1002/1097-0142(20000615)88:12<2677::AID-CNCR5>3.0.CO

[13]

2-B

[14]

BUCCHERI G, 2003, LUNG CANCER S4, V41, pS228

[15] A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older [J].

Chen, YM ;

Perng, RP ;

Chen, MC ;

Tsai, CM ;

Ming-Liu, J ;

Whang-Peng, J .

LUNG CANCER, 2003, 40 (02) :221-226

[16] Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer [J].

Choi, IS ;

Kim, BS ;

Park, SR ;

Lee, SY ;

Kim, DY ;

Kim, JH ;

Lee, SHO ;

Kim, TY ;

Heo, DS ;

Bang, YJ ;

Kim, NK .

LUNG CANCER, 2003, 39 (01) :99-101

[17] WEEKLY VINORELBINE IN ELDERLY PATIENTS WITH NON-SMALL-CELL LUNG-CANCER [J].

COLLEONI, M ;

GAION, F ;

NELLI, P ;

COLMELLERE, GM ;

MANENTE, P .

TUMORI, 1994, 80 (06) :448-452

[18]

COMELLA G, 2003, P AN M AM SOC CLIN, V22, P629

[19]

Cuzzoni Q, 2000, ANN ONCOL, V11, P3

[20] The role of vindesine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer: A phase III randomized FONICAP trial [J].

De Marinis, F ;

Rinaldi, M ;

Ardizzoni, A ;

Bruzzi, P ;

Pennucci, MC ;

Portalone, L ;

D'Aprile, M ;

Ripanti, P ;

Romano, F ;

Belli, M ;

Altavilla, G ;

Migliorino, MR ;

Rosso, R ;

Salvati, F .

TUMORI, 1999, 85 (03) :177-182

← 1 2 3 4 5 6 7 8 9 10 →